← Back to headlines
Novo Nordisk Considered a Better Buy Than Eli Lilly
A contrarian opinion suggests that Novo Nordisk is currently a more favorable investment than Eli Lilly, despite prevailing market sentiments.
28 May, 16:35 — 28 May, 16:35
Sources
Showing 1 of 1 sources
